Gamma-Dynacare Medical Laboratories (Gamma-Dynacare) announced that it has completed the acquisition of a controlling interest in Impact Genetics Inc. (Impact Genetics), a Toronto-based laboratory specializing in high-complexity, disease-specific genetic testing. “We welcome this opportunity to strengthen Gamma-Dynacare’s position as a leading Canadian reference laboratory,” said Naseem Somani, President and Chief Executive Officer, Gamma-Dynacare
Medical Laboratories. “Experts around the world seek out the specialized genetic testing expertise of Impact Genetics. This investment brings to Gamma-Dynacare expanded capabilities in molecular medicine, oncology and genetic testing for rare diseases that will enhance our continued growth in the field of personalized medicine.” Impact Genetics is recognized by oncologists and geneticists around the world as a leader in genetic testing for rare diseases. With a test menu
including Retinoblastoma RB,Hereditary Hemorrhagic Telangiectasia (HHT), Von Hippel-Lindau Syndrome
VHL and Gene Copy Number Analysis, Impact Genetics serves clients throughout North America, Asiaand Europe.
New tests for Uveal Melanoma and Inherited Leukemia will soon be launched. “This exciting partnership will provide Canadians with better genetics services and build on local expertise and talent in this rapidly expanding market,” said Franny Jewett, CEO, Impact Genetics. Over the coming months, Impact Genetics’ operations will move to Gamma-Dynacare’s centre of excellence for pathology, immunopathology, genetics and pharmacogenomics testing in Bowmanville Ontario, near Toronto. Ms. Jewett, Medical Director Dr. Brenda Gallie and the entire Impact Genetics team will remain in their respective roles with the company.
